RU2637367C2 - Светочувствительный химерный белок gpcr - Google Patents
Светочувствительный химерный белок gpcr Download PDFInfo
- Publication number
- RU2637367C2 RU2637367C2 RU2014101708A RU2014101708A RU2637367C2 RU 2637367 C2 RU2637367 C2 RU 2637367C2 RU 2014101708 A RU2014101708 A RU 2014101708A RU 2014101708 A RU2014101708 A RU 2014101708A RU 2637367 C2 RU2637367 C2 RU 2637367C2
- Authority
- RU
- Russia
- Prior art keywords
- protein
- gpcr
- chimeric
- mglur6
- cells
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 65
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 65
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims abstract description 100
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims abstract description 100
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 claims abstract description 96
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 claims abstract description 96
- 210000004027 cell Anatomy 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 210000001743 on-bipolar cell Anatomy 0.000 claims abstract description 50
- 210000001525 retina Anatomy 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 230000019491 signal transduction Effects 0.000 claims abstract description 28
- 230000002068 genetic effect Effects 0.000 claims abstract description 19
- 108091006027 G proteins Proteins 0.000 claims abstract description 16
- 102000030782 GTP binding Human genes 0.000 claims abstract description 16
- 108091000058 GTP-Binding Proteins 0.000 claims abstract description 16
- 230000007850 degeneration Effects 0.000 claims abstract description 16
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 238000002651 drug therapy Methods 0.000 claims abstract description 13
- 230000004438 eyesight Effects 0.000 claims abstract description 13
- 201000004569 Blindness Diseases 0.000 claims abstract description 11
- 102000005962 receptors Human genes 0.000 claims abstract description 10
- 108020003175 receptors Proteins 0.000 claims abstract description 10
- 230000004393 visual impairment Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000009261 transgenic effect Effects 0.000 claims abstract description 4
- 239000013604 expression vector Substances 0.000 claims abstract 11
- 230000003834 intracellular effect Effects 0.000 claims description 49
- 102100025912 Melanopsin Human genes 0.000 claims description 31
- 108010005417 melanopsin Proteins 0.000 claims description 31
- 108091008695 photoreceptors Proteins 0.000 claims description 28
- 230000002186 photoactivation Effects 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 230000002207 retinal effect Effects 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 16
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 11
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 238000010361 transduction Methods 0.000 claims description 10
- 230000026683 transduction Effects 0.000 claims description 10
- 210000002569 neuron Anatomy 0.000 claims description 9
- 101000720986 Homo sapiens Melanopsin Proteins 0.000 claims description 7
- 102000010175 Opsin Human genes 0.000 claims description 7
- 108050001704 Opsin Proteins 0.000 claims description 7
- 208000018769 loss of vision Diseases 0.000 claims description 7
- 231100000864 loss of vision Toxicity 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 101100122490 Drosophila melanogaster Galphaq gene Proteins 0.000 claims description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 4
- 230000004377 improving vision Effects 0.000 claims description 4
- 101000844510 Homo sapiens Transient receptor potential cation channel subfamily M member 1 Proteins 0.000 claims description 3
- 102000003617 TRPM1 Human genes 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 239000002262 Schiff base Substances 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 150000004753 Schiff bases Chemical class 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 210000003986 cell retinal photoreceptor Anatomy 0.000 abstract description 4
- 239000012528 membrane Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 239000013646 rAAV2 vector Substances 0.000 description 11
- 238000001415 gene therapy Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229930195712 glutamate Natural products 0.000 description 8
- 210000000608 photoreceptor cell Anatomy 0.000 description 8
- 208000003098 Ganglion Cysts Diseases 0.000 description 7
- 206010034972 Photosensitivity reaction Diseases 0.000 description 7
- 208000005400 Synovial Cyst Diseases 0.000 description 7
- 230000036211 photosensitivity Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004330 Rhodopsin Human genes 0.000 description 6
- 108090000820 Rhodopsin Proteins 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000004061 bleaching Methods 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 108091006116 chimeric peptides Proteins 0.000 description 5
- 230000031146 intracellular signal transduction Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000004298 light response Effects 0.000 description 4
- 101150024395 rab1A gene Proteins 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 108010041667 G Protein-Coupled Inwardly-Rectifying Potassium Channels Proteins 0.000 description 3
- 102000000542 G Protein-Coupled Inwardly-Rectifying Potassium Channels Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 102000006239 metabotropic receptors Human genes 0.000 description 3
- 108020004083 metabotropic receptors Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000013608 rAAV vector Substances 0.000 description 3
- 210000001116 retinal neuron Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- NCYCYZXNIZJOKI-HPNHMNAASA-N 11Z-retinal Natural products CC(=C/C=O)C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HPNHMNAASA-N 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001057 ionotropic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 238000012250 transgenic expression Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical class C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001405932 Conus mus Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000944266 Homo sapiens G protein-activated inward rectifier potassium channel 1 Proteins 0.000 description 1
- 101001032837 Homo sapiens Metabotropic glutamate receptor 6 Proteins 0.000 description 1
- 101000611338 Homo sapiens Rhodopsin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 101001032836 Mus musculus Metabotropic glutamate receptor 6 Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000003372 electrophysiological method Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001067 neuroprotector Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 210000003569 retinal bipolar cell Anatomy 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500863P | 2011-06-24 | 2011-06-24 | |
| US61/500,863 | 2011-06-24 | ||
| PCT/CH2012/000138 WO2012174674A1 (en) | 2011-06-24 | 2012-06-22 | Light-sensitive chimeric gpcr protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014101708A RU2014101708A (ru) | 2015-07-27 |
| RU2637367C2 true RU2637367C2 (ru) | 2017-12-04 |
Family
ID=46456289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014101708A RU2637367C2 (ru) | 2011-06-24 | 2012-06-22 | Светочувствительный химерный белок gpcr |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10112984B2 (enExample) |
| EP (2) | EP3029063B1 (enExample) |
| JP (1) | JP6240067B2 (enExample) |
| KR (1) | KR102008538B1 (enExample) |
| CN (2) | CN107383184A (enExample) |
| AU (1) | AU2012272505B2 (enExample) |
| BR (2) | BR122022007044B1 (enExample) |
| CA (1) | CA2840458C (enExample) |
| DK (1) | DK3029063T3 (enExample) |
| ES (1) | ES2766398T3 (enExample) |
| HR (1) | HRP20200004T1 (enExample) |
| HU (1) | HUE047074T2 (enExample) |
| LT (1) | LT3029063T (enExample) |
| PL (2) | PL2723767T3 (enExample) |
| PT (1) | PT3029063T (enExample) |
| RU (1) | RU2637367C2 (enExample) |
| SI (1) | SI3029063T1 (enExample) |
| WO (1) | WO2012174674A1 (enExample) |
| ZA (1) | ZA201308824B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140087463A1 (en) * | 2012-09-25 | 2014-03-27 | The Washington University | Optical control of cell signaling |
| EP3007730A1 (en) * | 2013-06-11 | 2016-04-20 | Friedrich Miescher Institute for Biomedical Research | Retinal on bipolar cells-specific artificial promoter |
| GB201403260D0 (en) | 2014-02-25 | 2014-04-09 | Univ Manchester | Treatment of retinal degeneration using gene therapy |
| CN110267972A (zh) * | 2016-11-06 | 2019-09-20 | 纳秒示波器科技有限公司 | 由多特征视蛋白进行的用于视力恢复的光学调制以及其其他应用 |
| EP3318285A1 (en) * | 2016-11-08 | 2018-05-09 | Oxford University Innovation Limited | Treatment of eye disease |
| EP3709871A4 (en) | 2017-11-13 | 2021-12-01 | The Regents of The University of California | COMPOSITIONS AND METHODS TO IMPROVE VISUAL FUNCTION |
| CN111527384B (zh) * | 2018-01-02 | 2023-08-29 | 昕诺飞控股有限公司 | 光黑视素活性指示器 |
| CN114041057A (zh) | 2019-04-29 | 2022-02-11 | 康福治疗有限公司 | 嵌合蛋白和筛选与gpcr结合的化合物和配体的方法 |
| EP4051694B1 (en) | 2019-10-31 | 2025-07-02 | Universität Bern | Aav vector variants for ocular gene delivery |
| CR20220283A (es) * | 2019-11-29 | 2022-09-30 | Univ Bern | Proteínas gpcr de opsinas quiméricas |
| WO2021140205A1 (en) * | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
| CN114762723A (zh) * | 2020-12-31 | 2022-07-19 | 吴伯骥 | HrpZpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用 |
| CN112675293A (zh) * | 2020-12-31 | 2021-04-20 | 吴伯骥 | HrpNEcb蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用 |
| EP4536694A1 (en) * | 2022-06-07 | 2025-04-16 | Adverum Biotechnologies, Inc. | Melanopsin variants for vision restoration |
| CN118791624B (zh) | 2023-04-11 | 2026-04-03 | 苏州星明优健生物技术有限公司 | 用于治疗视网膜神经退行性疾病的新型gpcr嵌合视蛋白 |
| WO2026017073A1 (zh) * | 2024-07-16 | 2026-01-22 | 北京脑科学与类脑研究所 | 一种光敏蛋白及其应用 |
| CN120442622A (zh) * | 2024-09-23 | 2025-08-08 | 中眸医疗科技(武汉)有限公司 | 多种在on型双极细胞上高效靶定的启动子在基因治疗技术中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059081A2 (en) * | 2004-11-30 | 2006-06-08 | Imperial Innovations Limited | Methods of treatment using melanopsin |
| EA018788B1 (ru) * | 2008-08-22 | 2013-10-30 | Андрей Александрович ИВАЩЕНКО | Лиганд с широким спектром фармакологической активности и его применение |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10507934A (ja) * | 1995-07-26 | 1998-08-04 | エヌピーエス・ファーマシウティカルズ・インコーポレイテッド | 代謝指向型グルタミン酸受容体に活性を示す化合物を同定するためのキメラ受容体および方法、ならびに神経学的障害および疾患の治療におけるそのような化合物の使用 |
| WO2004009022A2 (en) | 2002-07-18 | 2004-01-29 | The General Hospital Corp. | Method for augmenting vision in persons suffering from photoreceptor cell degeneration |
| WO2007131180A2 (en) * | 2006-05-04 | 2007-11-15 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| EP1891976A1 (en) * | 2006-08-23 | 2008-02-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research | Use of light sensitive genes |
| US8178496B2 (en) * | 2007-12-21 | 2012-05-15 | The Regents Of The University Of California | Photoreactive regulator of glutamate receptor function and methods of use thereof |
| EP2315833B8 (en) * | 2008-05-20 | 2015-05-27 | Eos Neuroscience, Inc. | Vectors for delivery of light-sensitive proteins and methods of use |
| NZ602416A (en) * | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
-
2012
- 2012-06-22 US US14/128,155 patent/US10112984B2/en active Active
- 2012-06-22 JP JP2014516148A patent/JP6240067B2/ja active Active
- 2012-06-22 EP EP15201713.3A patent/EP3029063B1/en active Active
- 2012-06-22 RU RU2014101708A patent/RU2637367C2/ru active
- 2012-06-22 AU AU2012272505A patent/AU2012272505B2/en active Active
- 2012-06-22 SI SI201231720T patent/SI3029063T1/sl unknown
- 2012-06-22 HU HUE15201713A patent/HUE047074T2/hu unknown
- 2012-06-22 LT LTEP15201713.3T patent/LT3029063T/lt unknown
- 2012-06-22 BR BR122022007044-2A patent/BR122022007044B1/pt active IP Right Grant
- 2012-06-22 CA CA2840458A patent/CA2840458C/en active Active
- 2012-06-22 BR BR112013033028A patent/BR112013033028A8/pt not_active Application Discontinuation
- 2012-06-22 PL PL12731288T patent/PL2723767T3/pl unknown
- 2012-06-22 ES ES15201713T patent/ES2766398T3/es active Active
- 2012-06-22 CN CN201710294286.2A patent/CN107383184A/zh active Pending
- 2012-06-22 CN CN201280030926.4A patent/CN103814045B/zh active Active
- 2012-06-22 EP EP12731288.2A patent/EP2723767B8/en active Active
- 2012-06-22 KR KR1020147000648A patent/KR102008538B1/ko not_active Expired - Fee Related
- 2012-06-22 DK DK15201713.3T patent/DK3029063T3/da active
- 2012-06-22 WO PCT/CH2012/000138 patent/WO2012174674A1/en not_active Ceased
- 2012-06-22 PT PT152017133T patent/PT3029063T/pt unknown
- 2012-06-22 PL PL15201713T patent/PL3029063T3/pl unknown
-
2013
- 2013-11-22 ZA ZA2013/08824A patent/ZA201308824B/en unknown
-
2020
- 2020-01-03 HR HRP20200004TT patent/HRP20200004T1/hr unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006059081A2 (en) * | 2004-11-30 | 2006-06-08 | Imperial Innovations Limited | Methods of treatment using melanopsin |
| EA018788B1 (ru) * | 2008-08-22 | 2013-10-30 | Андрей Александрович ИВАЩЕНКО | Лиганд с широким спектром фармакологической активности и его применение |
Non-Patent Citations (1)
| Title |
|---|
| YAMASHITA T. The second cytoplasmic loop of metabotropic glutamate receptor functions at the third loop position of rhodopsin, J. Biochem., 2001, v.130, is.1, p.149-155. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3029063B1 (en) | Light-sensitive chimeric gpcr protein | |
| US12343408B2 (en) | AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells | |
| US8470790B2 (en) | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids | |
| ES2538468T3 (es) | Vectores para la administración de proteínas sensibles a la luz y métodos para su utilización | |
| CN110267673A (zh) | 利用chrimson来进行光遗传视觉恢复 | |
| WO2021204407A1 (en) | G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd) | |
| US8734780B2 (en) | Methods for treating cardiac pacing conditions | |
| US20230338581A1 (en) | G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd) | |
| HK40004342A (en) | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner |